S
SaNOtize
An innovative biotech company, using a patented platform technology for topical delivery of NO, to treat upper respiratory and dermal infections
About SaNOtize
A pharmaceutical company that develops and commercializes nitric oxide-based therapies. Its primary technology is a Nitric Oxide Releasing Solution (NORS™) designed to treat a variety of microbial infections. The company's initial focus has been on upper respiratory infections, including COVID-19, for which it has developed a nasal spray shown to reduce viral load.
The business model revolves around the development and subsequent commercialization of its patented NORS™ technology. This includes conducting clinical trials to prove efficacy and safety, obtaining regulatory approvals in different jurisdictions, and then marketing its products to both healthcare providers and consumers. The company serves a global market, with a focus on regions where respiratory infections are prevalent. It generates revenue through the sale of its products, such as its antiviral nasal spray, and potentially through licensing its technology to other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Vancouver, Canada
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2022 | $24M | $96M | Horizons Ventures · ABC International · OurCrowd | ↗ |
| EARLY VC✓Equity / VC | Aug 2022 | $10M | $40M | OurCrowd | ↗ |
Growth signals
Latest recorded traffic for SaNOtize is 3.5K monthly website visits, up 29.6% over the last three months. SaNOtize's team declined 35.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Angel Forum
Series A7 investors entered at this stage
OurCrowd- MCM.Y. Capital
ImpactAssets
Happiness Capital
Keiretsu Forum
Horizons Ventures- AIABC International
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SaNOtize on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SaNOtize’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.